kabutan

Shionogi & Co.,Ltd.(4507) Summary

4507
TSE Prime
Shionogi & Co.,Ltd.
2,637.5
JPY
-57.0
(-2.12%)
Dec 5, 1:33 pm JST
17.02
USD
Dec 4, 11:33 pm EST
Result
PTS
outside of trading hours
2,637
Dec 5, 1:32 pm JST
Summary Chart Historical News Financial Result
PER
11.9
PBR
1.57
Yield
2.50%
Margin Trading Ratio
14.47
Stock Price
Dec 5, 2025
Opening Dec 5, 9:00 am
2,650.5 JPY 17.08 USD
Previous Close Dec 4
2,694.5 JPY 17.34 USD
High Dec 5, 9:00 am
2,661.5 JPY 17.15 USD
Low Dec 5, 9:03 am
2,627.0 JPY 16.93 USD
Volume
864,900
Trading Value
2.29B JPY 0.01B USD
VWAP
2641.45 JPY 17.04 USD
Minimum Trading Value
263,750 JPY 1,702 USD
Market Cap
2.35T JPY 0.02T USD
Number of Trades
3,131
Liquidity & Number of Trades
As of Dec 5, 2025
Liquidity
High
1-Year Average
4,287
1-Year High Apr 7, 2025
13,762
Margin Trading
Date Short Interest Long Margin Positions Ratio
Nov 28, 2025 204,100 444,500 2.18
Nov 21, 2025 205,800 404,400 1.97
Nov 14, 2025 206,200 394,600 1.91
Nov 7, 2025 119,600 483,000 4.04
Oct 31, 2025 125,300 523,600 4.18
Company Profile
Shionogi & Co., Ltd. has seen significant growth in its anti-HIV drugs. The company has strengths in hyperlipidemia medications, pain management, and the infection field. It is also accelerating its expansion into overseas markets.
Sector
Pharmaceuticals
Shionogi & Co., Ltd. engages in the research and development, procurement, manufacturing, and sales of prescription pharmaceuticals, with a particular strength in the field of infectious diseases. The company has numerous subsidiaries and affiliated companies both domestically and internationally, enabling a global business operation. Key subsidiaries include Shionogi Pharma, which handles manufacturing and contract manufacturing; Shionogi Healthcare, which develops OTC pharmaceutical business; and Shionogi TechnoAdvance Research, which provides research support for drug discovery. Overseas, Shionogi has established bases primarily in the United States, as well as in Europe and Asia, to promote local research and development and sales activities. In China, in particular, the company operates through multiple subsidiaries, demonstrating its active pursuit of expansion into foreign markets.